- Home
- CCIF vs KPTI Comparison
CCIF vs KPTI Comparison
Compare CCIF & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 47.6M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CCIF | KPTI |
|---|---|---|
| Price | $2.68 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 115.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $2.57 | $1.79 |
| 52 Week High | $5.95 | $10.99 |
Technical Indicators
Market Signals| Indicator | CCIF | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | N/A |
| Support Level | $2.72 | N/A |
| Resistance Level | $2.95 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.67 | 0.00 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).